| Literature DB >> 26405846 |
Russell Jones1, Michaela Marschmann1, Michael Keller2, Na Hong Qiu1, Stephen Fowler1, Thomas Singer1, Franz Schuler1, Christoph Funk1, Simone Schadt1.
Abstract
1. In recent years, the minipig is increasingly used as a test species in non-clinical assessment of drug candidates. While there is good scientific evidence available concerning cytochrome P450-mediated metabolism in minipig, the knowledge of other metabolic pathways is more limited. 2. The aim of this study was to provide an understanding of when, why, and how drug metabolism in minipig differs from other species commonly used in non-clinical studies. In-house cross-species metabolite profile comparisons in hepatocytes and microsomes of 38 Roche development compounds were retrospectively analyzed to compare the metabolism among minipig, human, rat, dog, monkey, rabbit and mouse. 3. A significant contributor to the elevated metabolism observed for certain compounds in minipig was identified as amide hydrolysis. The hepatic amide hydrolysis activity in minipig was further investigated in subcellular liver fractions and a structure-activity relationship was established. When structural motifs according to the established SAR are excluded, coverage of major human metabolic pathways was shown to be higher in minipig than in dog, and only slightly lower than in cynomolgus monkey. 4. A strategy is presented for early identification of drug compounds which might not be suited to further investigation in minipig due to excessive hydrolytic metabolism.Entities:
Keywords: Amide hydrolysis; biotransformation; drug metabolism; esterase; in vitro; metabolite; minipig; species differences
Mesh:
Substances:
Year: 2015 PMID: 26405846 DOI: 10.3109/00498254.2015.1089452
Source DB: PubMed Journal: Xenobiotica ISSN: 0049-8254 Impact factor: 1.908